Efficacy of Using Solum IV and BMC With GFC in TLIF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-30

Study Completion Date

2018-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the efficacy of using Solum IV and bone marrow concentrate with general fluid concentrate in Transforaminal Lumbar Interbody Fusion (TLIF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Bone Marrow Concentrate in Elective Tranforaminal Lumbar Interbody Fusion Surgery

NCT03793530

Bone Marrow Spinal Fusion

UNKNOWN NA

Transforaminal Lumbar Interbody Fusion (TLIF)

NCT04073563

Degenerative Disease of the Lumbosacral Spine

ACTIVE_NOT_RECRUITING NA

Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion

NCT07187362

Disc Degenerative Disease Spine Fusion for Degenerative Spine Disease

COMPLETED PHASE2/PHASE3

A Study Evaluating 3-Level OLIF Spine Fusion

NCT03896347

Spondylolisthesis Retrolisthesis Degenerative Disc Disease

WITHDRAWN

Safety Study of Mesenchymal Stem Cells and Spinal Fusion

NCT01552707

Lumbar Spondylolisthesis Involving L4-L5, and/or Degenerative Discopathy Involving L4-L5

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an TLIF with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's BMC with GFC.

The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).

All study subjects will be assessed for fusion rate, complication rates and subject-reported outcomes at designated intervals up to 12 months after surgery. X-rays (anterior-posterior, lateral, flexion-extension) will be taken at pre-operatively, 3, 6, and 12 months post-treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease Isthmic-lytic Spondylolisthesis Degenerative Spondylolisthesis Spinal Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an Transforaminal Lumbar Interbody Fusion (TLIF) with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's bone marrow concentrate with general fluid concentrate (GFC).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.

Group Type OTHER

Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion

Intervention Type COMBINATION_PRODUCT

The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion

The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is skeletally mature and older than 18 years of age
2. One and contiguous 2 or 3 level primary lumbar fusions.
3. L1 to S1 with a primary diagnosis of one or more of the following:

1. Degenerative disc disease,
2. Isthmic-lytic spondylolisthesis,
3. Degenerative spondylolisthesis
4. Spinal stenosis.
4. Subject has received conservative (non -surgical treatment for back pain for a minimum of 6 months and is unresponsive
5. Subject understand the conditions of enrollment and is willing to sign and date the informed consent form
6. Subject agrees to comply with study visits

\-

Exclusion Criteria

1. Previous bilateral Iliac Crest Bone Graft (ICBG) harvest
2. Previous instrumented fusion at the same or adjacent level
3. Active systemic infection, infection localized to the site of implantation or at aspiration site
4. Vulnerable patients

1. Nursing home residents
2. Prisoners
3. Other institutionalized persons
4. Persons with decisional incapacity
5. Pregnant women or interested in becoming pregnant in the next 12 months
6. Subjects with certain autoimmune diseases (such as lupus)
7. Subject has progressive neuromuscular disease
8. Active hepatitis, AIDS, ARS or is HIV positive
9. Syringomyelia at any spinal levels
10. Any other condition that would interfere with the subject self-assessment of pain, function or quality of life
11. Subjects with multiple allergies
12. Subjects with any history of cancer (except for basal cell carcinoma of the skin)
13. Significant osteoporosis
14. Subject is younger than or equal to 18 years of age
15. Subjects with a BMI of 40 or greater
16. Subject has diabetes mellitus requiring daily insulin management
17. Subject has allergy to implant materials (such as titanium, titanium alloy)
18. Subject has primary or metastatic tumors involving the spine
19. Subject is participating in another investigational study for a similar purpose
20. Subject has a history of significant mental illness or mental incapacity
21. Subject is currently smoker and will not cease smoking from the time of study enrollment up through 3 months post-operatively, nicotine users for whom post-operative bone stimulation would be prescribed, or has a recent history of alcohol or other substance abuse within the past 2 years
22. Subject is receiving workers compensation
23. Absence of English language reading or writing skills

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes